Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)
Cell and Gene Therapy for Personalised Medicine (CGT4PM2027) supports multinational research teams developing and validating novel cell and gene therapies to improve health outcomes through personalised medicine.
Funder: Austrian Science Fund (FWF)
Due Dates: January 20, 2027, 2:00 pm CET (Pre-proposals) | May 25, 2027, 2:00 pm CEST (Full proposals)
Funding Amounts: Approximately €33 million call budget; €200,000–€450,000 per FWF applicant, subject to national-annex exceptions; minimum two years
Summary: Supports multinational research developing and validating novel cell and gene therapies for personalised medicine across all disease areas.
Key Information: Teams apply jointly across countries, but each partner must meet its own regional or national funder’s eligibility rules.
Description
The fourth European Partnership for Personalised Medicine (EP PerMed) call supports innovative research in human health focused on developing and validating novel cell and gene therapies for personalised medicine. It welcomes all disease areas and covers somatic cell therapeutics, gene therapeutics, combined cell and gene therapeutics, and novel biological products—including mRNA, other nucleic acid-based methods, and extracellular vesicles used as vehicles for gene-based therapeutic procedures.
The call seeks multinational collaboration among academic, clinical/public-health, and private research teams. Its wider goal is improved health outcomes within sustainable healthcare systems. Interdisciplinary work and cross-sector collaboration are encouraged, including end-user perspectives, patient organisations, and regulatory or health technology assessment agencies. The Joint Call Secretariat at the French National Research Agency coordinates the call; Austrian funding involves FWF and Fonds Zukunft Österreich, with European Union co-funding.
